To improve the performance of our website, show the most relevant news products and targeted advertising, we collect technical impersonal information about you, including through the tools of our partners. You can find a detailed description of how we use your data in our Privacy Policy. For a detailed description of the technologies, please see the Cookie and Automatic Logging Policy.
By clicking on the Accept & Close button, you provide your explicit consent to the processing of your data to achieve the above goal.
You can withdraw your consent using the method specified in the Privacy Policy.
Accept & Close
Sputnik International
Members of India’s Covid Working Group don’t think so. 2 hours ago A health worker prepares to administer a dose of the Covishield, AstraZeneca-Oxford s Covid-19 coronavirus vaccine, at a vaccination centre in Mumbai on April 1. | Punit Paranjpe / AFP
On May 13, when the Indian government increased the duration between two doses of the Covishield vaccine to 12 weeks-16 weeks from eight weeks-six weeks, it cited “real life evidences, particularly from UK”.
The decision, according to members of India’s Covid Working Group that recommended it, was driven by studies that suggested that the first dose of the vaccine, developed by Oxford University and the British-Swedish company AstraZeneca, provided substantial protection.
Lifting lockdown on June 21 is not inevitable , Adam Kucharski, assistant professor in Infectious Disease Epidemiology at London School of Hygiene and Tropical Medicine, has warned.